Biotech News

Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update

Medicenna Therapeutics Corp. (MDNA)Medicenna Therapeutics Corp.Earnings

MDNA11 Phase 1/2 ABILITY-1 completes 152-patient enrollment and demonstrates 40% objective response rate (ORR) and 80% disease control rate (DCR) in biomarker-enriched gastrointestinal cancers The melanoma data were similarly encouraging, with ORRs of 30% and 38% in secondary and primary

Related news

Medicenna Therapeutics Corp.

IL-2 Superkine Platform Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology. MDNA11 MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being...

Recent company news

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States